Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Soueidan, S. A.
Right arrow Articles by Dalakas, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Soueidan, S. A.
Right arrow Articles by Dalakas, M. C.
NEUROLOGY 1993;43:876
© 1993 American Academy of Neurology

Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin

Shawke A. Soueidan, MD and Marinos C. Dalakas, MD

Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.

We report the treatment of four patients with inclusion-body myositis (IBM) and severe slowly progressive weakness using high-dose intravenous immunoglobulin (IVIg). After two monthly infusions, the strength of the proximal and less atrophic muscle groups improved or normalized in three of the four patients. The improvement lasted from 2 to 4 months. Intravenous immunoglobulin is the first treatment modality to improve the strength of some muscles in patients with this disabling inflammatory myopathy. In view of the high cost of IVIg, the unexpected but encouraging results from this pilot study warrant a controlled trial.

Address correspondence and reprint requests to Dr. Marinos C. Dalakas, Neuromuscular Diseases Section, Building 10, Room 4N248, NINDS, NIH, Bethesda, MD 28092.

Received June 12,1992. Accepted for publication in final form September 29, 1992.




This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A A Amato and R J Barohn
Inclusion body myositis: old and new concepts
J. Neurol. Neurosurg. Psychiatry, November 1, 2009; 80(11): 1186 - 1193.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. C. Dalakas
Inflammatory, immune, and viral aspects of inclusion-body myositis
Neurology, January 24, 2006; 66(1_suppl_1): S33 - S38.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
R. C. Griggs
The current status of treatment for inclusion-body myositis
Neurology, January 24, 2006; 66(1_suppl_1): S30 - S32.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
C M Wiles, P Brown, H Chapel, R Guerrini, R A C Hughes, T D Martin, P McCrone, J Newsom-Davis, J Palace, J H Rees, et al.
Intravenous immunoglobulin in neurological disease: a specialist review
J. Neurol. Neurosurg. Psychiatry, April 1, 2002; 72(4): 440 - 448.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
B. N. Mukunda, P. Dileep Kumar, and H. R. Smith
Long-Lasting Effectiveness of Intravenous Immunoglobulin in a Patient with Inclusion-Body Myositis
Ann Intern Med, June 19, 2001; 134(12): 1156 - 1156.
[Full Text] [PDF]

Home page
 NeurologyHome page
M. C. Dalakas, B. Koffman, M. Fujii, S. Spector, K. Sivakumar, and E. Cupler
A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM
Neurology, February 13, 2001; 56(3): 323 - 327.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. C. Walter, H. Lochmuller, P. Reilich, T. Klopstock, R. Huber, M. Hartard, M. Hennig, D. Pongratz, and W. Muller-Felber
Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study
Neurology, May 9, 2000; 54(9): 1848 - 1850.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
P. S. Sorensen
Intravenous Immunoglobulin Treatment in Neurologic Disorders: Yes
Arch Neurol, August 1, 1999; 56(8): 1025 - 1027.
[Full Text] [PDF]

Home page
 Arch NeurolHome page
D. Karussis and O. Abramsky
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?: No
Arch Neurol, August 1, 1999; 56(8): 1028 - 1032.
[Full Text] [PDF]

Home page
 NeurologyHome page
M. Naumann, K. V. Toyka, A. A. Amato, and R. T. Shebert
Inclusion body myositis in twins
Neurology, August 1, 1999; 53(3): 656 - 656.
[Full Text]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
F L Mastaglia, B A Phillips, and P J Zilko
Immunoglobulin therapy in inflammatory myopathies
J. Neurol. Neurosurg. Psychiatry, July 1, 1998; 65(1): 107 - 110.
[Abstract] [Full Text]

Home page
 Arch NeurolHome page
M. C. Dalakas, D. P. Stein, C. Otero, E. Sekul, E. J. Cupler, and S. McCrosky
Effect of High-Dose Intravenous Immunoglobulin on Amyotrophic Lateral Sclerosis and Multifocal Motor Neuropathy
Arch Neurol, September 1, 1994; 51(9): 861 - 864.
[Abstract] [PDF]

Home page
 NEJMHome page
M. C. Dalakas, I. Illa, J. M. Dambrosia, S. A. Soueidan, D. P. Stein, C. Otero, S. T. Dinsmore, and S. McCrosky
A Controlled Trial of High-Dose Intravenous Immune Globulin Infusions as Treatment for Dermatomyositis
N. Engl. J. Med., December 30, 1993; 329(27): 1993 - 2000.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by AAN Enterprises, Inc.